WAVE Life Sciences (WVE) Projected to Announce Quarterly Earnings on Tuesday

WAVE Life Sciences (NASDAQ:WVE) is anticipated to release its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $4.51 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. The firm had revenue of $2.27 million during the quarter, compared to the consensus estimate of $7.45 million. On average, analysts expect WAVE Life Sciences to post ($1.12) EPS for the current fiscal year and ($1.29) EPS for the next fiscal year.

WAVE Life Sciences Stock Performance

NASDAQ:WVE opened at $3.18 on Monday. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73. The stock has a market capitalization of $627.19 million, a P/E ratio of -2.92 and a beta of -1.43. The company’s 50-day simple moving average is $4.23 and its 200-day simple moving average is $5.59.

Analyst Upgrades and Downgrades

A number of research firms recently commented on WVE. Wedbush set a $13.00 target price on shares of WAVE Life Sciences in a research report on Friday, October 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of WAVE Life Sciences in a research note on Friday, October 2nd. B. Riley Financial cut their price target on shares of WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Finally, LADENBURG THALM/SH SH started coverage on WAVE Life Sciences in a research report on Thursday, October 1st. They set a “buy” rating and a $10.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, WAVE Life Sciences has an average rating of “Moderate Buy” and an average target price of $21.53.

Insider Activity

In other news, Director Adrian Rawcliffe sold 12,700 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Heidi L. Wagner sold 7,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director owned 44,930 shares in the company, valued at approximately $270,029.30. This trade represents a 13.48% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 23,564 shares of company stock valued at $132,476. Corporate insiders own 24.34% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.